Multimodal imaging has the potential for non-invasive assessment of imaging biomarkers that guide and monitor treatment of glioblastoma tumours. In this work, an imaging protocol for characterization of implanted patient-derived and murine glioblastoma tumours (GBM2, GBM14, and U87) was established using T2-weighted MRI, DWI, hyperpolarized 13C-pyruvate-lactate CSI, and 18F-FDG PET. Tumours were visible in T2-weighted MRI as high-signal regions with poorly defined borders. Compared with shams and non-tumour brain, all tumour lines had elevated ADC, 18F-FDG Ki, and lactate-to-pyruvate ratio. GBM2 had particularly high and variable lactate-to-pyruvate ratio, despite relatively low variability in ADC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords